#RepresentationMatters 🦓 #RareDiseases aren’t always visible.
I live with #TGCT, a rare, unpredictable joint tumor that causes pain, stiffness & mobility limitations.
And yet, 1 in 10 Americans has a rare disease. Rare ≠ alone. #RareDisease #ShowYourStripes #PVNS

@rarediseaseadvisor.bsky.social for rare disease month, Tenosynovial Giant Cell Tumors would be a good thing to spotlight. We are fighting for visibility too + as a patient, I’ve always needed abundance of resources like @stern-sydney.bsky.social TGCT support to guide me. #TGCT #rarediseasemonth

It’s #ASCO2026 submission day! May everyone get their abstracts in 🙏 excited for another #TGCT and #rareoncology filled ASCO #TGCTSupport

🆕 New publication alert 🚨
PC-RPLND from patients with TGCTs: key morphologic variants, diagnostic pitfalls, and clinical impact—read & share!

🔗 www.sciencedirect.com/science/arti...

#pathtwitter #pathX #gupath #TGCT #IUPathology #indianapath @iupathology

European Commission approves vimseltinib for treatment of TGCT - SPAGN - Sarcoma Patient Advocacy Global Network September 2025 – The European Commission approved vimseltinib for the treatment of adults with symptomatic tenosynovial giant cell tumor (TGCT) not qualifying for surgery and with clinically relevant…

🚀 Big step forward for TGCT: EMA has accepted the marketing authorization application for vimseltinib, potentially making it the first approved treatment in Europe for symptomatic TGCT when surgery isn’t viable. Read more at: bit.ly/VimseltinibN...

#TGCT #Sarcoma

When that #CTOS2025 email hits 🎉🎉🎉🎉🎉 Very excited to represent TGCT Support at CTOS and present on #TGCT.

I’d like to thank my co-authors 👏🏻👏🏻

Vimseltinib Approved in EU for Tenosynovial Giant Cell Tumor Vimseltinib has received EU approval for treating tenosynovial giant cell tumor, offering effective outcomes and improved patient quality of life.

Vimseltinib (ROMVIMZA™) Gains European Commission (EC) Approval as First Targeted Therapy for TGCT

oncodaily.com/new-paper-al...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Vimseltinib #ROMVIMZA #TGCT

European Commission approves ROMVIMZA for TGCT treatment - PharmaTimes Vimseltinib becomes first authorised therapy for tenosynovial giant cell tumour in the EU

#ROMVIMZA #Vimseltinib #TGCTtreatment #tenosynovialgiantcelltumour #EU #symptomatictenosynovialgiantcelltumour #TGCT #marketingauthorisation #TGCTtherapy #OnoPharmaceutical #Deciphera #phase3MOTIONstudy #Secondaryendpoints #tumourresponse #stiffness #qualityoflife
pharmatimes.com/news/europea...

Pediatric Tenosynovial Giant Cell Tumour: Insights from a 24‑Patient Study

24 TGCT cases (1998‑2023) showed knee involvement in 75% and 71% had arthroscopic synovectomy; over 8‑year follow‑up six recurrences occurred, all diffuse‑type knee lesions. getnews.me/pediatric-tenosynovial-g... #tgct #knee

European Commission Greenlights Vimseltinib for Symptomatic, Unresectable TGCT | OncLive Vimseltinib earned approval from the European Commission for the treatment of symptomatic, unresectable tenosynovial giant cell tumor.

European Commission Greenlights Vimseltinib for Symptomatic, Unresectable TGCT
#TGCT #EuropeApproval
www.onclive.com/view/europea...

💦💦💦

#tgct #hexuan #sketch #art #1page1day #scrapbooking #junkjournal #diary #journaling #collage #collageart #fanart

рыбка моя 💙

#tgct #hexuan

Breakthrough Emactuzumab Phase 3 TANGENT Trial in TGCT: SynOx Pharma Reports Enrollment Completed Ahead of Schedule - OncoDaily SynOx Pharma completes Phase 3 TANGENT trial enrollment for Emactuzumab in TGCT, with top-line results expected in early 2026.

Breakthrough Emactuzumab Phase 3 TANGENT Trial in TGCT: SynOx Pharma Reports Enrollment Completed Ahead of Schedule

@synox-tx.bsky.social

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Emactuzumab #TANGENT #TGCT #SynOx

Vimseltinib Earns Positive CHMP Recommendation for TGCT The EMA’s CHMP recommended the approval of vimseltinib for symptomatic tenosynovial giant cell tumor.

Vimseltinib Earns Positive CHMP Recommendation for TGCT #TGCT #Oncology
www.onclive.com/view/vimselt...

July is Sarcoma Awareness Month — and we’re claiming space for #TGCT!
TGCT is a connective tissue tumor that, like so many living with it, doesn’t quite fit neatly into a box. Join us in spreading awareness one story at a time!
#TGCTStrong #sarcomaawareness

Learn more at TGCTSupport.org

Abbisko Therapeutics Achieves Milestone with NMPA Acceptance for Pimicotinib Targeting TGCT Treatment Abbisko Therapeutics proudly announces the NMPA's acceptance of their NDA for Pimicotinib, an innovative drug aimed at treating TGCT, showcasing promising clinical efficacy.

Abbisko Therapeutics Achieves Milestone with NMPA Acceptance for Pimicotinib Targeting TGCT Treatment #China #Shanghai #Abbisko #Pimicotinib #TGCT

Conferences like #ASCO25 matter because they connect our patient-driven data and insights with the researchers shaping the future of GIST care. We’re there to advocate & amplify the patient voice in research & clinical trials. #GIST #TGCT #GCT #liposarcoma @liposarcomasupport.bsky.social

So proud, for my first #ASCO25, to present work on pediatric #TGCT on behalf of TGCT Support ☺️ grateful for the opportunity to raise awareness

Attending #ASCO25? Be sure to visit poster board 📋27 at 9:00 AM ⏰

Did you know that pediatric pts w/ diffuse #TGCT undergo an average of 3.4 surgeries? These young pts need coordinated, MD care to manage the long-term physical + emotional impact of this disease. Learn more !

Thanks @stern-sydney.bsky.social! I am humbled and credits should go to you for all that you are doing for the #TGCT community and beyond! Looking forward to seeing your presentation! 😀 #CTOSTweeTOS #Sarcoma

Tumori: risultati positivi per pimicotinib, farmaco in sviluppo per Tgct (Adnkronos) - Nel trattamento dei pazienti con tumore a cellule giganti tenosinoviale (Tgct) sono positivi - per efficacia significativa e miglioramenti clinici rilevanti - i risultati della Parte 1 dello studio globale di fase 3 Maneuv...

Tumori: risultati positivi per pimicotinib, farmaco in sviluppo per Tgct ... LEGGI TUTTO #tumore #pimicotinib #Tgct #ricerca #oncologia

Check out more findings from our pediatric #TGCT real-world evidence at #ASCO25 in T-Minus 2 days !

Don’t miss our poster
📍 Hall A, sarcoma session
📆 Saturday, May 31st, 9:00 - 12:00 pm
📋 27

#RWE #pediatric #oncology

As you make your #ASCO25 schedules, visit our poster on Pediatric #TGCT, an ultra-rare, under-recognized neoplasm in desperate need of progress. Pediatric TGCT mimics the adult form but lack the therapeutic advancement.

Sarcoma poster @ 9:00-12:00pm CDT on May 31st, 2025

@ascocancer.bsky.social

Today Lianlian went to check how his carrots are doing! 🥕

#XieLian #TGCT

Romvimza™ (vimseltinib) is FDA-approved for symptomatic tenosynovial giant cell tumor, where surgery risks serious outcomes. The phase 3 trial showed a 40% ORR vs. 0% for placebo. A promising new option.
📄 Find the clinical evidence for Romvimza at: drugdocs.com/drug/Romvimza
#TGCT #Romvimza #FDA

Sit back. Relax. And celebrate Cinco de Mayo by learning about our #TGCT registry:

youtu.be/flaM6eRCgd4?...

Read the paper here: www.tandfonline.com/doi/full/10....

Excited to be attending @ASCO for the first time ever AND presenting about #TGCT in pediatric patients #ASCO25

Can’t wait to see everyone in ☀️ Chicago at the end of the month!

a man in a suit and tie is sitting in the back seat of an airplane ALT: a man in a suit and tie is sitting in the back seat of an airplane

It's not as if my GP didn't see the results of the pathology on the tumor they removed. But I find out #TGCT could explain a lot more about my pain and disability, by accident, while trying to get a good explainer citation for an article I'm working on, about growing up with chronic pain. FFS. [4/4]

Fancy that. 20 years of pain from a fingertip growth no one could see, it's finally removed and I'm told rather nonchalantly that it was just a GCT. Meanwhile, my lower body pain has increased, while my mobility has decreased, significantly for the last 15 years. And #TGCT is NEVER mentioned. [1/4]

FDA Grants Fast Track Designation to Emactuzumab for Unresectable TGCT The FDA granted fast track designation to emactuzumab for unresectable tenosynovial giant cell tumor.

FDA Grants Fast Track Designation to Emactuzumab for Unresectable TGCT
#TGCT @fda.gov
www.onclive.com/view/fda-gra...